109 related articles for article (PubMed ID: 21378221)
1. High radioactive iodine uptake despite a fully suppressed TSH in a patient with thyroid cancer.
Stathatos N; Gaz R; Ross DS; Daniels GH
J Clin Endocrinol Metab; 2011 Mar; 96(3):589. PubMed ID: 21378221
[No Abstract] [Full Text] [Related]
2. Graves' disease, thyroid nodules and thyroid cancer.
Belfiore A; Russo D; Vigneri R; Filetti S
Clin Endocrinol (Oxf); 2001 Dec; 55(6):711-8. PubMed ID: 11895209
[No Abstract] [Full Text] [Related]
3. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
4. [Main trends and controversies in treatment of patients with diffuse toxic goiter and thyroid gland cancer].
Romanchishen AF; Vabalaĭte KV
Vestn Khir Im I I Grek; 2011; 170(3):58-63. PubMed ID: 21848241
[No Abstract] [Full Text] [Related]
5. Measurement of stimulating TSH receptor antibodies in sera of patients with Graves' disease by a recombinant TSH receptor bioassay.
Derwahl M; Schatz H; Bolle B; Pohl A; Meyer K
Exp Clin Endocrinol; 1992; 100(1-2):75-9. PubMed ID: 1361452
[No Abstract] [Full Text] [Related]
6. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.
Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S
Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462
[TBL] [Abstract][Full Text] [Related]
7. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine.
Teng CS; Yeung RT; Khoo RK; Alagaratnam TT
J Clin Endocrinol Metab; 1980 Jun; 50(6):1005-10. PubMed ID: 6103007
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment for malignant thyroid disease.
Berg G
Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
[TBL] [Abstract][Full Text] [Related]
10. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
Kosugi S; Ban T; Akamizu T; Kohn LD
Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
[TBL] [Abstract][Full Text] [Related]
11. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
12. [Graves' disease].
Izumi Y; Amino N
Ryoikibetsu Shokogun Shirizu; 2000; (31):92-5. PubMed ID: 11269198
[No Abstract] [Full Text] [Related]
13. Thyroid cancer.
Carling T; Udelsman R
Annu Rev Med; 2014; 65():125-37. PubMed ID: 24274180
[TBL] [Abstract][Full Text] [Related]
14. Production of non-stimulatory immunoglobulins that inhibit TSH binding in Graves' disease after radioiodine administration.
Bech K; Bliddal H; Siersbaek-Nielsen K; Friis T
Clin Endocrinol (Oxf); 1982 Oct; 17(4):395-402. PubMed ID: 6128089
[No Abstract] [Full Text] [Related]
15. Encapsulated insular carcinoma of the thyroid arising in graves' disease: report of a case and review of the literature.
Foroughi F; Saadat N; Salehian MT
Int J Surg Pathol; 2012 Dec; 20(6):636-9. PubMed ID: 22689614
[TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine.
Hamdy O; Raafat S; Saleh GA; Atallah K; M Saleh M; Shebl AM; Hegazy MA
Ann R Coll Surg Engl; 2019 May; 101(5):e122-e124. PubMed ID: 30854863
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy for hyperthyroidism.
Ross DS
N Engl J Med; 2011 Feb; 364(6):542-50. PubMed ID: 21306240
[No Abstract] [Full Text] [Related]
18. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW
J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
[TBL] [Abstract][Full Text] [Related]
19. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
20. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
